Fertility sparing management of endometrial adenocarcinoma and atypical hyperplasia: A literature review;Traitement conservateur du cancer et des hyperplasies atypiques de l'endomètre en vue de préserver la fertilité: Revue de la littérature

Bulletin du Cancer

Volumn 99, Issue 1, 2012, Pages 51-60

  Koskas, Martin ^a   Yazbeck, Chadi ^a   Walker, Francine ^a   Delorme, Pierre ^a   Azria, Elie ^a   Luton, Dominique ^a   Madelenat, Patrick ^b  

^a BICHAT HOSPITAL   (France)

^b Services d'Anatomopathologie ^*  (France)

Author keywords

Adenocarcinoma; Atypical hyperplasia; Conservative management; Endometrium; Fertility sparing

Indexed keywords

GESTAGEN;

ATYPICAL HYPERPLASIA; CANCER REGRESSION; ENDOMETRIUM CARCINOMA; FOLLOW UP; HYPERPLASIA; INFERTILITY THERAPY; OUTCOME ASSESSMENT; PREGNANCY; RECURRENCE RISK; REVIEW;

EID: 84856559943     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1516     Document Type: Article

References (44)

1. Navarria I, Usel M, Rapiti E, et al. Young patients with endometrial cancer: How many could be eligible for fertility-sparing treatment?. Gynecol Oncol 2009; 114 : 448-51.
2. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. J Epidemiol Biostat 2001; 6 : 47-86.
3. Gitsch G, Hanzal E, Jensen D, Hacker NF. Endometrial cancer in premenopausal women 45 years and younger. Obstet Gynecol 1995; 85 : 504-8.
4. Yasuda M, Matsui N, Kajiwara H, et al. Malignant transformation of atypical endometrial hyperplasia after progesterone therapy showing germ-cell tumor-like differentiation. Pathol Int 2004; 54 : 451-6. (Pubitemid 38829933)
5. Ferrandina G, Zannoni GF, Gallotta V, Foti E, Mancuso S, Scambia G. Progression of conservatively treated endometrial carcinoma after full term pregnancy: a case report. Gynecol Oncol 2005; 99 : 215-7. (Pubitemid 41354604)
6. Cormio G, Martino R, Loizzi V, Resta L, Selvaggi L. A rare case of choroidal metastasis presented after conservative management of endometrial cancer. Int J Gynecol Cancer 2006; 16 : 2044-8. (Pubitemid 44924369)
7. Ota T, Yoshida M, Kimura M, Kinoshita K. Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger. Int J Gynecol Cancer 2005; 15 : 657-62. (Pubitemid 41022904)
8. Ushijima K, Yahata H, Yoshikawa H, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in youngwomen. J Clin Oncol 2007; 25 : 2798-803. (Pubitemid 47123189)
9. Kim YB, Holschneider CH, Ghosh K, Nieberg RK, Montz FJ. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer 1997; 79 : 320-7. (Pubitemid 27029896)
10. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997; 90 : 434-40. (Pubitemid 27357938)
11. Kaku T, Yoshikawa H, Tsuda H, et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett 2001; 167 : 39-48. (Pubitemid 32373267)
12. Gotlieb WH, Beiner ME, Shalmon B, et al. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol 2003; 102 : 718-25. (Pubitemid 37206407)
13. Jadoul P, Donnez J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. Fertil Steril 2003; 80 : 1315-24.
14. Niwa K, Yokoyama Y, Tanaka T, et al. Successful pregnancy in a patient with endometrial carcinoma treated with medroxyprogesterone acetate. Arch Gynecol Obstet 1994; 255 : 91-4. (Pubitemid 24194222)
15. Minaguchi T, Nakagawa S, Takazawa Y, et al. Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium. Cancer Lett 2007; 248 : 112-22.
16. Yang XH, Guo YQ, Fu Y, et al. Measuring fatty acid concentration in maize grain by near-infrared reflectance spectroscopy. Guang Pu Xue Yu Guang Pu Fen Xi 2009; 29 : 106-9.
17. Elizur SE, Beiner ME, Korach J, Weiser A, Ben-Baruch G, Dor J. Outcome of in vitro fertilization treatment in infertile women conservatively treated for endometrial adenocarcinoma. Fertil Steril 2007; 88 : 1562-7. (Pubitemid 350225705)
18. Yamazawa K, Hirai M, Fujito A, et al. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod 2007; 22 : 1953-8. (Pubitemid 47062765)
19. Signorelli M, Caspani G, Bonazzi C, Chiappa V, Perego P, Mangioni C. Fertility-sparing treatment in young women with endometrial cancer or atypical complex hyperplasia: a prospective single-institution experience of 21 cases. BJOG 2009; 116 : 114-8.
20. Han AR, Kwon YS, Kim DY, et al. Pregnancy outcomes using assisted reproductive technology after fertility-preserving therapy in patients with endometrial adenocarcinoma or atypical complex hyperplasia. Int J Gynecol Cancer 2009; 19 : 147-51.
21. Yu M, Yang JX, Wu M, Lang JH, Huo Z, Shen K. Fertility-preserving treatment in young women with well-differentiated endometrial carcinoma and severe atypical hyperplasia of endometrium. Fertil Steril 2009; 92 : 2122-4.
22. Mazzon I, Corrado G, Masciullo V, Morricone D, Ferrandina G, Scambia G. Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. Fertil Steril 2009; 93 : 1286-9.
23. Stanosz S. An attempt at conservative treatment in selected cases of type I endometrial carcinoma (stage I a/G1) in young women. Eur J Gynaecol Oncol 2009; 30 : 365-9.
24. Hahn HS, Yoon SG, Hong JS, et al. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer 2009; 19 : 1068-73.
25. Mao Y, Wan X, Chen Y, Lv W, Xie X. Outcomes of conservative therapy for young women with early endometrial adenocarcinoma. Fertil Steril 2010; 93 : 283-5.
26. Minig L, Franchi D, Boveri S, Casadio C, Bocciolone L, Sideri M. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women. Ann Oncol 2011; 22 : 643- 9.
27. Laurelli G, Di Vagno G, Scaffa C, Losito S, Del Giudice M, Greggi S. Conservative treatment of early endometrial cancer: preliminary results of a pilot study. Gynecol Oncol 2011; 120 : 43-6.
28. Eftekhar Z, Izadi-Mood N, Yarandi F, Shojaei H, Rezaei Z, Mohagheghi S. Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients. Int J Gynecol Cancer 2009; 19 : 249-52.
29. Wang CB, Wang CJ, Huang HJ, et al. Fertility-preserving treatment in young patients with endometrial adenocarcinoma. Cancer 2002; 94 : 2192-8.
30. Imai M, Jobo T, Sato R, Kawaguchi M, Kuramoto H. Medroxy-progesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations. Eur J Gynaecol Oncol 2001; 22 : 217-20. (Pubitemid 32757874)
31. Purdie DM. Epidemiology of endometrial cancer. Rev Gynaecol Pract 2003; 3 : 217-20. (Pubitemid 40418193)
32. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999; 17 : 1736-44. (Pubitemid 29269242)
33. Emons G, Schroder B, Ortmann O, Westphalen S, Schulz KD, Schally AV. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 1993; 77 : 1458-64. (Pubitemid 24000896)
34. Kung FT, Chen WJ, Chou HH, Ko SF, Chang SY. Conservative management of early endometrial adenocarcinoma with repeat curettage and hormone therapy under assistance of hysteroscopy and laparoscopy. Hum Reprod 1997; 12 : 1649-53.
35. Yazbeck C, Dhainaut C, Thoury A, Driguez P, Madelenat P. Conservative treatment of endometrial cancer and atypical hyperplasia. Gynecol Obstet Fertil 2004; 32 : 433-41. (Pubitemid 38765997)
36. Yarali H, Bozdag G, Aksu T, Ayhan A. A successful pregnancy after intracytoplasmic sperm injection and embryo transfer in a patient with endometrial cancer who was treated conservatively. Fertil Steril 2004; 81 : 214-6. (Pubitemid 38058353)
37. Kelley RM, Baker WH. Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med 1961; 264 : 216-22.
38. Grimbizis G, Tsalikis T, Tzioufa V, Kasapis M, Mantalenakis S. Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: a prospective study. Hum Reprod 1999; 14 : 479-84. (Pubitemid 29097406)
39. Agorastos T, Bontis J, Vakiani A, Vavilis D, Constantinidis T. Treatment of endometrial hyperplasias with gonadotropin-releasing hormone agonists: pathological, clinical, morphometric, and DNA-cytometric data. Gynecol Oncol 1997; 65 : 102-14. (Pubitemid 27171560)
40. Perez-Medina T, Bajo J, Folgueira G, Haya J, Ortega P. Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormone analogues: long-term follow-up. Gynecol Oncol 1999; 73 : 299-304. (Pubitemid 29215747)
41. Kresowik J, Ryan GL, Van Voorhis BJ. Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system. Obstet Gynecol 2008; 111 : 547-9. (Pubitemid 351156496)
42. Morice P, Fourchotte V, Sideris L, Gariel C, Duvillard P, Castaigne D. A need for laparoscopic evaluation of patients with endometrial carcinoma selected for conservative treatment. Gynecol Oncol 2005; 96 : 245-8. (Pubitemid 39612444)
43. Pinto AB, Gopal M, Herzog TJ, Pfeifer JD, Williams DB. Successful in vitro fertilization pregnancy after conservative management of endometrial cancer. Fertil Steril 2001; 76 : 826-9. (Pubitemid 32928414)
44. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009; 373 : 125-36.